TR201802943T4 - (S)-pirolidin-1,2-dikarboksilik asit 2-amid 1-({4-metil-5-[2-(2,2,2-trifloro-1,1-dimetil-etil)-piridin-4-il]-tiyazol-2-il}amid)'in egfr'ye bağlı hastalıkların veya egfr familya üyelerini hedefleyen ajanlara karşı direnç edinmiş hastalıkların tedavisinde kullanımı. - Google Patents
(S)-pirolidin-1,2-dikarboksilik asit 2-amid 1-({4-metil-5-[2-(2,2,2-trifloro-1,1-dimetil-etil)-piridin-4-il]-tiyazol-2-il}amid)'in egfr'ye bağlı hastalıkların veya egfr familya üyelerini hedefleyen ajanlara karşı direnç edinmiş hastalıkların tedavisinde kullanımı. Download PDFInfo
- Publication number
- TR201802943T4 TR201802943T4 TR2018/02943T TR201802943T TR201802943T4 TR 201802943 T4 TR201802943 T4 TR 201802943T4 TR 2018/02943 T TR2018/02943 T TR 2018/02943T TR 201802943 T TR201802943 T TR 201802943T TR 201802943 T4 TR201802943 T4 TR 201802943T4
- Authority
- TR
- Turkey
- Prior art keywords
- egfr
- treatment
- amide
- disease
- thiazol
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title claims abstract 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract 19
- OAWXZFGKDDFTGS-BYPYZUCNSA-N (2s)-pyrrolidine-1,2-dicarboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(O)=O OAWXZFGKDDFTGS-BYPYZUCNSA-N 0.000 title claims 4
- -1 2,2,2-trifluoro-1,1-dimethyl-ethyl Chemical group 0.000 title claims 4
- 230000001419 dependent effect Effects 0.000 title claims 3
- 108060006698 EGF receptor Proteins 0.000 title abstract description 16
- 230000008685 targeting Effects 0.000 title abstract description 4
- 239000003795 chemical substances by application Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims abstract 10
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract 4
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 5
- 229960002584 gefitinib Drugs 0.000 claims description 5
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical group C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 5
- 229960000575 trastuzumab Drugs 0.000 claims description 2
- 229940121647 egfr inhibitor Drugs 0.000 claims 11
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 9
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 9
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 5
- KUFRQPKVAWMTJO-LMZWQJSESA-N alvespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C1C2=O KUFRQPKVAWMTJO-LMZWQJSESA-N 0.000 claims 4
- 229950007861 alvespimycin Drugs 0.000 claims 4
- 229960005395 cetuximab Drugs 0.000 claims 3
- 229950010203 nimotuzumab Drugs 0.000 claims 3
- 229960001972 panitumumab Drugs 0.000 claims 3
- 101100402572 Arabidopsis thaliana MS5 gene Proteins 0.000 claims 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 2
- 229960001433 erlotinib Drugs 0.000 claims 2
- 229960004891 lapatinib Drugs 0.000 claims 2
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 2
- 229950008001 matuzumab Drugs 0.000 claims 2
- 229960002087 pertuzumab Drugs 0.000 claims 2
- SWDZPNJZKUGIIH-QQTULTPQSA-N (5z)-n-ethyl-5-(4-hydroxy-6-oxo-3-propan-2-ylcyclohexa-2,4-dien-1-ylidene)-4-[4-(morpholin-4-ylmethyl)phenyl]-2h-1,2-oxazole-3-carboxamide Chemical compound O1NC(C(=O)NCC)=C(C=2C=CC(CN3CCOCC3)=CC=2)\C1=C1/C=C(C(C)C)C(O)=CC1=O SWDZPNJZKUGIIH-QQTULTPQSA-N 0.000 claims 1
- QULDDKSCVCJTPV-UHFFFAOYSA-N BIIB021 Chemical compound COC1=C(C)C=NC(CN2C3=NC(N)=NC(Cl)=C3N=C2)=C1C QULDDKSCVCJTPV-UHFFFAOYSA-N 0.000 claims 1
- 101150029707 ERBB2 gene Proteins 0.000 claims 1
- 102100031672 Homeobox protein CDX-1 Human genes 0.000 claims 1
- 101000777808 Homo sapiens Homeobox protein CDX-1 Proteins 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 claims 1
- 229950005069 luminespib Drugs 0.000 claims 1
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 102000001301 EGF receptor Human genes 0.000 abstract description 14
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 8
- 229940126062 Compound A Drugs 0.000 description 4
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 102000038030 PI3Ks Human genes 0.000 description 3
- 108091007960 PI3Ks Proteins 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 101710113864 Heat shock protein 90 Proteins 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
- 102000007348 bcl-Associated Death Protein Human genes 0.000 description 1
- 108010007734 bcl-Associated Death Protein Proteins 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960003685 imatinib mesylate Drugs 0.000 description 1
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 108010041420 microbial alkaline proteinase inhibitor Proteins 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000007755 survival signaling Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Formül (I)'e ait bileşiklerin, Epidermal Büyüme Faktörü Reseptörüne (EGFR) bağlı hastalıkların veya EGFR familyasının üyelerini hedefleyen ajanlara direnç kazanmış olan hastalıkların tedavisinde kullanımı; adı geçen bileşiklerin, adı geçen hastalıkların tedavisine yönelik farmasötik kompozisyonların üretiminde kullanımı, adı geçen bileşiklerin adı geçen kullanım için EGFR modülatörleri ile kombinasyonu, adı geçen hastalıkların, adı geçen hastalıkların adı geçen bileşikler ile tedavisine yönelik yöntemler ve adı geçen hastalıkların tedavisine yönelik olup adı geçen bileşikleri tek başlarına veya özellikle bir EGFR modülatörü ile kombinasyon halinde içeren farmasötik preparasyonlar.
Description
Tarifname içerisinde atifta bulunulan patent dökümanlari:
Tarifnamede belirtilen patentlestirilmemis literatür:
° PAEZ et al. GF R mutations in lung
cancer: correlation With clinical
respoiise to gefitinib therapy. Science,
0 KOBAYASHI et al. EGFR mutation
and resistance of non-sinall cell lung
° GORRE et al. Bcr-Abl point mutants
isolated from patients with imatinib
mesylate resistant chronic
leukemia reinain sensitive to inhibitors
of the Bcr-Abl chaperone heat shock
protein 90. Blood, 2002, vol.
° ANTONESCU et al. Acquired
resistance to Imatinib in gastrointestinal
stromal tumors occurs through
secondary gene mutation. Clin Cancer
° ZHAO et al. The pl 10 alpha isoform
of PI3K is essential for proper growth
transformation. PNAS, 2006, vol. 103,
o ENGELMAN et al. ErbB-3 mediates
phosphoinositide 3-kinase activity in
gefitinib-sensitive non small cell lung
cancer cell lines. PNAS, 2005, vol.
- ENGELMAN et al. Allelic dilution
obscures detection of a biologically
significant resistance mutation in
EGFR amplified lung cancer. The
Journal of Clinical Investigation, 2006,
o CHAN et al. Differential sensitivities
of trastuzumab (Herceptin(R))-resistant
human breast cancer cells to
phosphoinositide-3 kinase (Pl-3K) and
epidermal growth factor receptor
(EGF R) kinase inhibitors. Breast and
Cancer Research and Treatment, 2005,
° SHE et al. The BAD protein
integrates survival signaling
by EGFR/MAPI( and Pl3K/Akt kinase
pathways in PTEN-deficient tumor
o Mendelsohn and Baselga; Status of
Epidermal Growth Factor Receptor
Antagonists in the Biology
and Treatinent of Cancer. Journal of
o Mendelsohn and Baselga; Epidermal
Growth Factor Receptor Targeting in
Cancer. Seminars in Oncology,
° SERGINA et al. Escape from HER-
family tyrosine kinase inhibitor therapy
by the kinase-inactive HER 3. Nature,
o IRMER et al. EGFR kinase domain
mutations - functional
impact and relevance for lung cancer
o ROCHE-LIMA et al. EGFR
targeting of solid tumors. Cancer
SEKILLERDEKI YAZILARIN ANLAMLARI
A = Araç 10 mL/kg p.o. q24sa
B : Bilesik A 50 mg/kg p.0. q24sa
C = Tümör hacmi (ortalaina mm3 ±SEM)
D = Tümör implantasyonu sonrasi günler
E = Vücut agirligi degisikligi (%)
F = Ortalama±SEM
G = Bilesik A 12,5 mg/kg p.0. q24sa
H = Bilesik A 25 mg/kg p.0. q24sa
J = Hücre enjeksiyonu sonrasi süre (Günler)
K = Clark ve arkadaslari tarafindan (2000) yayinlanmis olan yöntem
kullanilarak sinerjistik etki isaret edildi: CI: -O.12
L =Tedavi baslangiç
N = Kombinasyon Bilesik A+
Cnc_ ..En n. m2. uc.. n umrusnnwmw; Ibn.
.v ...1. .. Ex.. .. L!. u. . :....tihiisizp .. v
..43 .un i.. ...n
Claims (2)
1-({4- il}~-aniid) ve gefitinib, erlotinib, lapatinib, NVP-AEE778, AV412, anti-EGFR monoklonal antikoru 806, anti-EGFR inonoklonal antikoru-Y90/Re-188, setuksimab, panitumumab, matuzumab, nimotuzumab, zalutumurnab, pertuzumab, MDX- 214, CDXllO, IMCllFS, pertuzuinab, trastuzuinab, TDMl, Zemab®, the Her2 asisi FX 1041 ve HSP90 inhibitörleri CNFlOlO, CNF2024, tanespimisin, alvespimisin, IP1504, SNX5422 ve NVP-AUY922'nin olusturdugu gruptan seçilen bir EGFR modülatörü, ki buradaki aktif muhteviyatlar, her bir durumda serbest formda veya farmasötik açidan kabul gören bir tuz formundadir, ve istege göre en az bir farmasötik açidan kabul gören tasiyici içeren kombinasyon. Istein lO°a göre kullanim için kombinasyon; buradaki EGFR niodülatörü, trastuzumabdir. EGFR”ye bagli bir hastaligin veya bir EGFR modulat'orü ile tedavi sirasinda direnç kazanmis olan bir hastaligin tedavisine yönelik bir yöntemde kullaniin için bir (S)-Pirolidin-l,2- dikarboksilik asit
2-aniid l-({4-metil-5-[2-(2,2,2-trifloro-l,1- dimetil-etil)-piridin-4-il]-tiyazol-2-il}-amid) bilesigi. Istein lZ'ye göre kullaiiiin için bir bilesik; buradaki bilesik, istem 5 ”e göre bir EGFR inhibitörü ile birlikte uygulanir. EGFR”ye bagli bir hastaligin veya bir EGFR modülat'orü ile tedavi sirasinda direnç kazaninis olan bir hastaligin tedavisinde kullanim için olup, isteiii l'e göre bir (S)-Pirolidin-l,2- diineti1-eti1)-piridin-4-il]-tiyazol-Z-il} -ainid) bilesigi veya bunun farmasötik açidan kabul gören bir tuzunu ve farmasötik açidan kabul gören en az bir tasiyiciyi içeren bir farinasötik preparasyon; burada tedavi edilecek hastalik, gögüs kanseridir. Istem l4”e göre kullanim için olup, istem 5'e göre bir EGFR inhibitör'û içeren farmasötik preparasyon.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41111710P | 2010-11-08 | 2010-11-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
TR201802943T4 true TR201802943T4 (tr) | 2018-03-21 |
Family
ID=44947083
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2018/02943T TR201802943T4 (tr) | 2010-11-08 | 2011-11-07 | (S)-pirolidin-1,2-dikarboksilik asit 2-amid 1-({4-metil-5-[2-(2,2,2-trifloro-1,1-dimetil-etil)-piridin-4-il]-tiyazol-2-il}amid)'in egfr'ye bağlı hastalıkların veya egfr familya üyelerini hedefleyen ajanlara karşı direnç edinmiş hastalıkların tedavisinde kullanımı. |
Country Status (12)
Country | Link |
---|---|
US (4) | US20130209461A1 (tr) |
EP (1) | EP2637661B1 (tr) |
JP (4) | JP2013542228A (tr) |
KR (1) | KR101854484B1 (tr) |
CN (2) | CN105412105A (tr) |
AU (1) | AU2011328227B2 (tr) |
BR (1) | BR112013009624A2 (tr) |
CA (1) | CA2815492C (tr) |
MX (1) | MX360157B (tr) |
RU (1) | RU2589695C2 (tr) |
TR (1) | TR201802943T4 (tr) |
WO (1) | WO2012062694A1 (tr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6180420B2 (ja) * | 2011-10-14 | 2017-08-16 | ノバルティス アーゲー | 増殖性疾患の治療のためのhsp90阻害剤と組み合わせた2−カルボキサミドシクロアミノウレア誘導体 |
RU2014122198A (ru) * | 2011-11-02 | 2015-12-10 | Новартис Аг | Производные 2-карбоксамид циклоамино мочевины для применения в лечении vegf-зависимых заболеваний |
AU2013299841B8 (en) * | 2012-08-07 | 2017-01-05 | Array Biopharma Inc. | Pharmaceutical combinations comprising a B-Raf inhibitor, an EGFR inhibitor and optionally a PI3K-alpha inhibitor |
RU2705095C2 (ru) * | 2012-08-16 | 2019-11-05 | Новартис Аг | Комбинация ингибитора pik3 и ингибитора с-мет |
BR112015025101A2 (pt) * | 2013-04-05 | 2017-07-18 | Sanofi Sa | composição antitumoral que compreende um inibidor pi3kbeta-seletivo e um inibidor pi3kalfa-seletivo |
KR20160095035A (ko) * | 2013-12-06 | 2016-08-10 | 노파르티스 아게 | 알파-이소형 선택성 포스파티딜이노시톨 3-키나제 억제제를 위한 투여 요법 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY130778A (en) * | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
AR044519A1 (es) * | 2003-05-02 | 2005-09-14 | Novartis Ag | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina |
KR20100093129A (ko) * | 2007-12-20 | 2010-08-24 | 노파르티스 아게 | Pi 3 키나제 억제제로서 사용되는 티아졸 유도체 |
CA3146422A1 (en) * | 2008-03-18 | 2009-09-24 | Genentech, Inc. | Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use |
UA104147C2 (uk) * | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
-
2011
- 2011-11-07 TR TR2018/02943T patent/TR201802943T4/tr unknown
- 2011-11-07 EP EP11782111.6A patent/EP2637661B1/en active Active
- 2011-11-07 AU AU2011328227A patent/AU2011328227B2/en active Active
- 2011-11-07 CA CA2815492A patent/CA2815492C/en active Active
- 2011-11-07 RU RU2013126485/15A patent/RU2589695C2/ru active
- 2011-11-07 CN CN201510770643.9A patent/CN105412105A/zh active Pending
- 2011-11-07 KR KR1020137011803A patent/KR101854484B1/ko active IP Right Grant
- 2011-11-07 MX MX2013005182A patent/MX360157B/es active IP Right Grant
- 2011-11-07 BR BR112013009624A patent/BR112013009624A2/pt not_active IP Right Cessation
- 2011-11-07 JP JP2013537156A patent/JP2013542228A/ja active Pending
- 2011-11-07 US US13/879,644 patent/US20130209461A1/en not_active Abandoned
- 2011-11-07 CN CN2011800538729A patent/CN103200943A/zh active Pending
- 2011-11-07 WO PCT/EP2011/069522 patent/WO2012062694A1/en active Application Filing
-
2015
- 2015-05-26 US US14/721,064 patent/US20150250778A1/en not_active Abandoned
-
2016
- 2016-07-07 JP JP2016134705A patent/JP2016222686A/ja not_active Withdrawn
-
2018
- 2018-07-12 US US16/033,764 patent/US20180325883A1/en not_active Abandoned
- 2018-10-24 JP JP2018199647A patent/JP2019048822A/ja not_active Withdrawn
-
2019
- 2019-09-17 US US16/573,909 patent/US20200022967A1/en not_active Abandoned
-
2020
- 2020-03-26 JP JP2020056250A patent/JP2020114849A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2815492A1 (en) | 2012-05-18 |
EP2637661A1 (en) | 2013-09-18 |
JP2019048822A (ja) | 2019-03-28 |
JP2020114849A (ja) | 2020-07-30 |
JP2013542228A (ja) | 2013-11-21 |
AU2011328227A1 (en) | 2013-04-18 |
EP2637661B1 (en) | 2017-12-20 |
US20150250778A1 (en) | 2015-09-10 |
CN103200943A (zh) | 2013-07-10 |
KR101854484B1 (ko) | 2018-05-03 |
RU2589695C2 (ru) | 2016-07-10 |
US20130209461A1 (en) | 2013-08-15 |
MX2013005182A (es) | 2013-07-03 |
US20180325883A1 (en) | 2018-11-15 |
KR20130143582A (ko) | 2013-12-31 |
US20200022967A1 (en) | 2020-01-23 |
RU2013126485A (ru) | 2014-12-20 |
BR112013009624A2 (pt) | 2016-07-12 |
MX360157B (es) | 2018-10-24 |
WO2012062694A1 (en) | 2012-05-18 |
CN105412105A (zh) | 2016-03-23 |
CA2815492C (en) | 2019-04-09 |
AU2011328227B2 (en) | 2015-04-09 |
JP2016222686A (ja) | 2016-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7030750B2 (ja) | Lag-3に対する抗体分子およびその使用 | |
ES2878188T3 (es) | Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3 | |
ES2716685T3 (es) | Moléculas de anticuerpo para PD-1 y usos de las mismas | |
ES2771926T3 (es) | Terapias de combinación | |
US20160303127A1 (en) | Combination therapy with c-met and egfr antagonists | |
JP2020514356A (ja) | Ros1キナーゼ阻害剤としての大環状化合物 | |
CN107810011A (zh) | 使用抗ox40抗体治疗癌症的方法 | |
AU2009221164B2 (en) | Use of pyrimidine derivatives for the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family members | |
CN107750164A (zh) | 使用抗ox40抗体和pd‑1轴结合拮抗剂治疗癌症的方法 | |
BR112019020508A2 (pt) | anticorpos biespecíficos de ligação a erbb-2 e erbb3 para utilização no tratamento de células que possuem um gene de fusão nrg1 | |
TR201802943T4 (tr) | (S)-pirolidin-1,2-dikarboksilik asit 2-amid 1-({4-metil-5-[2-(2,2,2-trifloro-1,1-dimetil-etil)-piridin-4-il]-tiyazol-2-il}amid)'in egfr'ye bağlı hastalıkların veya egfr familya üyelerini hedefleyen ajanlara karşı direnç edinmiş hastalıkların tedavisinde kullanımı. | |
US11845994B2 (en) | Response to EGFR blockade | |
CN102224170A (zh) | 抑制与fgfr4相关的癌细胞侵袭的材料和方法 | |
CA3060407A1 (en) | Treatment of her2 positive cancers | |
RU2481838C2 (ru) | Применение имидазохинолинов для лечения заболеваний, зависимых от egfr, или заболеваний с приобретенной резистентностью к агентам, которые связываются с членами семейства egfr | |
CA3110658A1 (en) | Compounds, compositions and methods for treating or preventing her-driven cancers | |
Vazquez-Martin et al. | Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb®) in human breast carcinoma cells | |
WO2010120592A1 (en) | Combination therapy using an anti-egfr agent(s) and igf-1r specific inhibitors | |
KR20210110664A (ko) | Tam 및 met 키나제의 억제제로서의 퀴놀린 화합물 | |
JP2022027658A (ja) | チロシンキナーゼ阻害剤と併用してegf/egfr経路を抑制する方法および組成物 | |
JP2017520609A (ja) | 低悪性度漿液性癌におけるher3阻害 | |
WO2020219926A1 (en) | Treatment of cancer with cdk inhibitors | |
Sampera Borràs | Characterization of molecular mechanisms of acquired resistance to Trastuzumab in gastric cancer | |
Zaryouh | Novel, rationally designed combination strategies, based on (phospho) proteomic analyses, to enhance the response to cetuximab therapy in head and neck cancer | |
Shabaya et al. | Novel therapeutic strategies and combinations for HER2-overexpressing breast cancer |